Oramed Pharmaceuticals appoints Yadin Rozov to board of directors

ORAMED PHARMACEUTICALS INC.

Board size increased by one and Yadin Rozov appointed effective April 1, 2022.
Rozov has over 20 years experience in capital markets, corporate finance, and investment banking.
He is founder and managing partner of Terrace Edge Ventures LLC since January 2022.
Rozov previously served as Partner at GoldenTree Asset Management and CEO of Syncora Guarantee.
He will receive the same compensation as other non-executive directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Yadin Rozov

director

ORMP · ORAMED PHARMACEUTICALS INC.

Effective: 2022-04-01
Filed: April 4, 2022, 7:59 PM ET

On March 30, 2022, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Mr. Yadin Rozov to serve as a director to fill the resulting vacancy, effective as of April 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Yadin Rozov was appointed as director at ORAMED PHARMACEUTICALS INC..

Action: appointed
Role: director

Exact text from the filing

On March 30, 2022, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Mr. Yadin Rozov to serve as a director to fill the resulting vacancy, effective as of April 1, 2022.

View on SEC.gov

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001213900-22-017667

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.